Sign in Subscribe
Cancer

Breakthrough in Cancer Research: Proteomics Analysis Reveals Molecular Effectors of Anti-CD19 CAR-T Cell Therapy

Strategic Insights

— 1 min read

Researchers at the University of Sao Paulo have made significant strides in understanding the mechanism and signalling pathways of CAR-T cell therapy, a state-of-the-art approach in cell and immunotherapy. By employing global proteomics, the team identified proteins as molecular effectors of anti-CD19 CAR-T cell treatment during the early stages of CAR-T-target cell interaction. This study highlights the importance of understanding the connection between tumours and modified cells, paving the way for the development of new CAR constructs and improved efficacy in overcoming resistance to this innovative cancer treatment strategy.

Key Takeaways:

  • Researchers at the University of Sao Paulo have conducted a study to understand the mechanism and signalling pathways of CAR-T cell therapy.
  • The team employed global proteomics to identify proteins as molecular effectors of anti-CD19 CAR-T cell treatment during the early stages of CAR-T-target cell interaction.
  • The study identified proteins involved in antigen presentation, T-cell activation, and apoptosis, including CD247, CD28, DAP, LCK, p38 MAPK, and CASP3.
  • Pharmacological inhibition of LCK using Dasatinib further suggested its pivotal role in early CAR-T signalling.
  • The research has been peer-reviewed and published in the Journal of Proteomics.
  • The study has significant implications for the development of new CAR constructs and improved efficacy in overcoming resistance to CAR-T cell therapy.
  • The researchers aim to advance the identification of adjuvant molecules for the regulation of CAR-T responses.

Statistics:

  • Over 8800 protein identifications were made at 1% FDR using DIA methodology on the Orbitrap Astral LC-MS/MS platform.
  • The effector CAR-Jurkat cells showed proteomic changes involving antigen presentation by CD74.
  • The target RAJI B-cells exhibited more significant alterations, with 44% of proteins showing ≥ 1.4-fold changes.
  • The top 10 proteins identified as molecular effectors of anti-CD19 CAR-T cell therapy were CD247, CD28, DAP, LCK, p38 MAPK, CASP3, CD74, CD33, CD4, and CD8.
  • The study's findings have the potential to lead to the development of new CAR constructs and improved efficacy in overcoming resistance to CAR-T cell therapy.

Sources:

  • University of Sao Paulo:Dept. of Biochemistry and Immunology, Ribeirao Preto Medical School, Ribeirao Preto, Sao Paulo 14049-900, Brazil
  • Elsevier: Journal of Proteomics, Radarweg 29, 1043 Nx Amsterdam, Netherlands
  • Journal of Proteomics: www.journals.elsevier.com/journal-of-proteomics/
  • NewsRx LLC: Cancer Weekly, August 12, 2025; p 85

Read more